


## PRODUCT UPDATE

Company	Product	Development
Baxter Healthcare	Factor VIII	The European Community's (EC) Committee for Proprietary Medical Products has recommended the approval of Factor VIII to treat hemophilia A. This sets the stage for EC member countries to approve the product.
Biocine	gD2 vaccine	Results from phase II studies show that 98 patients with genital herpes who were vaccinated at 0 and 2 months with the gD2 immunotherapeutic experienced one-third fewer outbreaks than the control group.
BioCryst	BCX-34	BCX-34, an inhibitor of the enzyme purine nucleoside phosphorylase, showed efficacy in treating both cutaneous T-cell lymphoma and psoriasis in phase I/II trials.
Cell Therapeutics	CT-1501R	CT-1501R has commenced four clinical studies as a therapy to lessen the toxicities of chemotherapy and interleukin-2 therapies in cancer patients.
Centocor	Myoscint & Fibriscint	Centocor has withdrawn the product license applications (PLA) for Myoscint and Fibriscint following the discovery of deficiencies in the applications. The PLA for Myoscint, a monoclonal antibody (MAb) based cardiac imaging agent, was filed in 1988. The PLA for Fibriscint, a MAb-based blood-clot imaging agent, was filed in 1991.
Cor Therapeutics	Integrelin	Phase II results of Integrelin, a glycoprotein IIb-IIIa antagonist, indicate that it reduces clinical events when administered with aspirin and heparin as treatment for angioplasty.
Immunogen	Oncolysin B	Phase I results for Oncolysin B show that the immunoconjugate extended the remissions of 10 of 12 B-cell lymphoma patients. The patients were in remission subsequent to autologous bone-marrow transplants.
Liposome Technology	Doxil	Doxil, liposome-encapsulated doxorubicin hydrochloride, delivered five-to-eleven times more drug than comparable doses of Adriamycin, unencapsulated doxorubicin, to AIDS patients with Kaposi's sarcoma.
Matrix	MPI 5003	MPI 5003, an injectable therapeutic implant containing fluorouracil, will start phase III trials against genital warts. Phase II results showed that 65 percent of patients treated with the product had complete clearance of genital warts.
Matrix	MPI 5011	Early results from ongoing phase I/II trials of MPI 5011 are encouraging. The product is an injectable therapeutic implant for prostate cancer that contains 5-fluorouracil.
Medarex	MDX-210	Medarex is beginning phase I/II trials of a bispecific antibody, MDX-210, for breast and ovarian cancers.
Neoprobe	RIGScan CR49	Neoprobe will commence a second phase III trial for its RIGScan CR49, the radiolabeled-antibody component of its intraoperative cancer-detection system. The trial will evaluate patients diagnosed with metastatic colorectal cancer.
NeoRx	OncoTrac	NeoRx has commenced a limited clinical trial to qualify Boehringer Ingelheim as the manufacturer of its OncoTrac small-cell lung-cancer imaging kit.
Protein Design Labs	Antibodies	The Food and Drug Administration (FDA) has granted orphan drug status for certain indications to Protein Design Lab's human antibodies against cytomegalovirus and hepatitis B.
Ribi ImmunoChem	MPL-C	FDA has allowed an investigational new drug application to evaluate the prophylactic use of MPL-C immunomodulator to reduce the effects of cardiac ischemia-reperfusion injury. MPL-C is thought to increase production of a protective antioxidant enzyme in cardiac cells.
Sandoz	Interleukin-3	Sandoz has begun a phase III trial for combination therapy with interleukin-3 and granulocyte macrophage colony stimulating factor. The trial aims to reconstitute blood-cell populations following autologous bone-marrow transplantation in patients with Hodgkin's disease or non-Hodgkin's lymphoma.
Seragen	DAB <sub>389</sub> IL-2	Seragen has begun a phase I/II trial for early treatment of HIV with DAB <sub>389</sub> IL-2, the second version of its interleukin-2 receptor-targeted fusion toxin.
Seragen	DAB <sub>486</sub> IL-2	In a phase II trial, some patients with refractory rheumatoid arthritis showed clinical improvement after receiving three courses of DAB <sub>486</sub> IL-2, Seragen's initial interleukin-2 receptor-targeted fusion toxin.
Sphinx Pharmaceuticals	Kynac	Preliminary results of a phase II trial of Kynac ointment for treatment of psoriasis showed no statistically significant difference between Kynac and its ointment vehicle. Kynac inhibits the activity of the protein kinase C family of intracellular enzymes.



### AGBIOTECH

Crop Genetics	Spod-X	The Environmental Protection Agency (EPA) has approved Spod-X, a naturally occurring insect virus that controls <i>Spodoptera exiqua</i> , the beet armyworm. —Claire M. Corcoran
---------------	--------	--